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Abstract
The added value of a new drug can be defined in various ways, but the patient-focused approach 
obliges the clinical significance of additional health effects to be also considered. For any given new 
drug, the American Food and Drug Administration (FDA) determines the added value delivered 
to the current therapy standard by conducting an assessment based on: the extent of the delivered 
health effect regarding clinically significant endpoints, the duration of that effect and the importance 
of the clinical effect for treating a serious disease. In principle, preliminary scientific evidence for 
a new and original drug should clearly indicate an additional benefit compared to currently avail-
able therapeutic methods. In order to make such drugs available as quickly as possible to patients, 
the FDA has implemented programmes since the 1970s aimed at shortening development and ap-
proval processes of methods with therapeutic promise, particularly in treating patients suffering 
from serious diseases. The most recent programme of this type introduced by the FDA, grants an 
innovative drug the special status of a breakthrough therapy, from which the drug acquires numer-
ous privileges. In the last ten to twenty months the FDA granted several molecules this status, thus 
significantly shortening the patient waiting time for drug marketing. In the FDA’s opinion, such 
drugs offer breakthrough progress in treating patients with chronic lymphocytic leukemia.
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Streszczenie
Wartość dodaną nowego leku można definiować w różny sposób, jednak podejście zorientowane na 
chorego obliguje do uwzględnienia również istotności klinicznej dodatkowego efektu zdrowotnego. 
W celu określenia wartości dodanej względem aktualnego standardu leczenia amerykańska Agen-
cja ds. Żywności i Leków (FDA) przeprowadza ocenę nowego leku; wynik oceny zależy od wielkości 
oferowanego efektu zdrowotnego w zakresie istotnych klinicznie punktów końcowych, czasu utrzy-
mywania się tego efektu oraz znaczenia efektu klinicznego dla leczenia ciężkiego schorzenia. Co do 
zasady wstępne dowody naukowe dotyczące nowego, oryginalnego leku powinny jasno wskazywać 
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na dodatkową korzyść względem aktualnie dostępnych metod leczenia. W celu jak najszybszego 
udostępnienia chorym takiego leku w FDA od lat 70. ubiegłego wieku wdrażano programy służące 
skróceniu procesu rozwoju i rejestracji obiecującej metody leczenia, w szczególności gdy znajdowała 
zastosowanie w leczeniu chorych na ciężkie schorzenia. Najnowszy program tego typu wprowadzony 
przez FDA wiąże się z nadawaniem innowacyjnemu lekowi specjalnego statusu „breakthrough 
therapy”, dzięki któremu lek uzyskuje liczne przywileje. W okresie ostatnich kilkunastu miesięcy 
FDA wyróżniła tym statusem kilka cząsteczek, co umożliwiło znaczne skrócenie czasu oczekiwania 
chorych na udostępnienie leków na rynku. W ocenie FDA leki te oferują przełomowy postęp w le-
czeniu chorych na przewlekłą białaczkę limfocytową.
Słowa kluczowe: terapia przełomowa, FDA, przewlekła białaczka limfocytowa, obinutuzumab, 
ibrutynib, idelalizyb, zatwierdzenie leku
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Introduction
In 2006, the number of patients estimated by 
the FDA who received innovative drugs as part of 
clinical trials (IND, Investigational New Drug) in 
life-threatening situations, was over 100 000 cases 
[1]. For those tested drugs, which proved to be 
significantly more effective than existing thera-
peutic options, specially developed programmes 
have hitherto, long been attempted for making 
early and effective drug treatment available to 
patients. Such drug development acceleration 
programmes thereby shorten the clinical test pe-
riod, and provide early access for new therapeutic 
options to more patients. This is attested both by 
the Subpart E programme, which shortened mean 
clinical trials duration from 8.9 to 6.2 years, or the 
accelerated approval programme giving an average 
time reduction of 4.2 years [2].
A significantly reduced time for considering 
new drug approval applications by the FDA was also 
observed from over 30 months in 1980s to about 
10 months in 2011 [3]. However, in order to guar-
antee patient treatment safety, a significant part of 
registration decisions are conditional on carrying 
out additional Phase 4 studies (confirmatory stud-
ies); indeed, after 2000 about 80% of drugs under 
the accelerated approval procedure were required 
to conduct such studies [4].
The actual granting of the breakthrough ther-
apy designation introduced by the FDA in 2012, is 
an involved programme for maximally accelerat-
ing an otherwise restrictive and time-consuming 
administrative procedure. This procedure requires 
analysing the scientific evidence and reviewing the 
approval application for a drug intended to treat 
severe clinical conditions, for which preliminary 
scientific evidence indicates the possibility of sig-
nificant improvements to patient’s health regarding 
clinically significant endpoints when compared with 
the current therapy standards [5].
Recently, several innovative molecules have 
been granted breakthrough therapy status by 
the FDA. Particularly worth mentioning are the 
hematological drugs approved for treating CLL; 
obinutuzumab, ibrutinib and idelalisib.
Significance of breakthrough therapy 
status granted by FDA
The granting of such status expedites the 
evaluation of drugs used in treating life-threatening 
clinical conditions. The criteria for drug evaluation 
include preliminary clinical evidence, confirming 
significant improvement of at least one clinically 
significant endpoint when compared with the cur-
rent standard. According to the FDA, a clinically 
significant endpoint most frequently depends on 
the incidence, mortality or the consequences of 
severe disease. It can be also related to:
• an effect on a surrogate endpoint or interme-
diate clinical endpoint considered reasonably 
likely to predict a clinical benefit;
• an effect on a pharmacodynamic biomarker(s) 
that does not meet criteria for an acceptable 
surrogate endpoint, but strongly suggests the 
potential for a clinically meaningful effect on 
the underlying disease;
• significant improvement to both the safety 
profile and efficacy compared with the current 
therapy standards [6].
The procedure for granting drug breakthrough 
therapy status is like other fast track programmes 
and emphasises effectively decreasing the time 
taken in completing all formalities for granting mar-
keting authorisation, engaging the manufacturer’s 
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representatives and for efficiently using other fast 
track programmes. Details are described by the Food 
and Drug Administration Safety and Innovation Act 
(FDASIA) passed in 2012 by the USA Congress [7]. 
This states, that the breakthrough therapy status 
can be only granted to a drug which is:
• intended for monotherapy or in combination 
with other drugs when treating severe or 
life-threatening diseases or clinical conditions;
• when preliminary clinical data suggest signifi-
cant improvements may be afforded compared 
with existing therapies, regarding at least one 
clinically significant endpoint.
Severe disease and clinical conditions have 
been defined in the FDA Guidance for Industry 
— Expedited Programs for Serious Conditions 
— Drugs and Biologics. These state; “A disease 
or condition substantially limiting patient’s every-
day functioning. Short-lasting and spontaneously 
regressing diseases constitute no sufficient justifi-
cation. Moreover, the disease or clinical condition 
need not to be irreversible, if they are long-lasting 
or recurrent. Whether a given disease or clinical 
condition are serious, is a question of clinical as-
sessment, with consideration of the influence on 
such factors as: survival, everyday functioning, 
possibility of progression of the untreated disease”.
A manufacturer applying for breakthrough 
therapy status for a new drug, must demonstrate 
its effect on an important aspect of the disease, e.g. 
a direct effect on the symptoms of serious disease 
The application can be also justified by clinical 
benefits to patients that include:
• improving the diagnosis of serious disease, 
translated into better treatment results;
• reducing adverse reactions from the currently 
applied treatment;
• reducing serious adverse events compared 
with the current therapy standards [8].
Granting a drug breakthrough therapy status 
delivers tangible benefits to the manufacturer. For 
such drugs the regulations of the FDASIA act (sec-
tion 902), provide for the following:
1) substantial FDA support for the applicant 
on effective drug development programmes, 
starting from Phase I studies;
2) staff consultations with manufacture’s senior 
management about all benefits reserved for 
drugs approved in the fast track designa-
tion procedure;
3) consultations about optimal planning of pha- 
se III clinical trials,
4) appointing an interdisciplinary team of review-
ers for drug evaluation (specialists in medi-
cine, pharmacology, toxicology, chemistry, 
drug manufacturing, supervision and control);
5) appointing a leader of an interdisciplinary 
reviewing team and scientifically liaising be-
tween the team and sponsor;
6) involving experienced experts for interdisci-
plinary review of documentation submitted 
by a sponsor.
Ideally, the drug manufacturer should sub-
mit an application to the FDA for breakthrough 
therapy status before finalising the Phase II study 
preparation. Because this status is granted for 
speeding up the process of gathering and analysing 
scientific evidence (i.e. to support authorisation 
for the rapid marketing of any given new drugs), 
the FDA will not review any further applications 
after the final registration applications have been 
submitted; these being termed ‘Biologic License 
Applications’ (BLA) or ‘New Drug Applications’ 
(NDA). The 60 days reviewing period allotted 
to the FDA (for assigning breakthrough therapy 
status) is thus crucial to both manufacturers and 
patients awaiting a new treatment to become avail-
able. This, therefore obliges the FDA to prioritise 
such applications [9].
The key differences between granting drug 
breakthrough therapy status and drug approval in 
the fast track programme are the requirements 
that a new drug has to meet for qualification. 
In applying for breakthrough therapy status the 
criteria are very rigorous. A significant improve-
ment in clinical benefit to patients must be shown 
to a clinically significant endpoint, compared with 
current treatment standards. However to qualify 
for the fast track programme the FDA may grant 
those drugs with clinical or non-clinical data which 
suggest possible health benefits for patients with 
a serious disease, for whom no therapeutic options 
are available (unmet medical needs).
It is the manufacturer, who should usually sub-
mit an application for granting drug breakthrough 
therapy status, however if after reviewing the 
preliminary scientific evidence, the FDA consi-
ders the product meeting the adequate criteria and 
that the privileges associated with granting that 
status could expedite the availability of the drug 
to patients, then the office itself may suggest the 
manufacturer to submit such an application [9].
Chronic lymphocytic leukemia
This is a clonal lymphoproliferative disease, 
where B cell lymphocytes uncontrollably proliferate 
and accumulate in the peripheral blood, bone marrow, 
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lymph nodes, spleen and liver. These cells resemble 
small mature lymphocytes possessing B-line immu-
nophenotype and CD5 surface marker expression. 
CLL is the most commonly diagnosed leukemia in 
European and North American countries occurring 
at rates of 4.2/100,000 of the population.
CLL patients constitute a heterogeneous clini-
cal group, where in most cases the therapeutic goal 
includes obtaining a complete remission (CR), pro-
longation of the progression-free survival (PFS), 
improvement of the overall survival (OS) and the 
quality of life (QoL). Intensifying the therapy is not 
possible for all patients, particularly the elderly 
with numerous comorbidities (less fit or slow–go 
patients) [10]. In particular, the latter cases have 
rarely been considered for clinical trials, in which 
the median age of patients is usually 50–60 years, 
while in the general population the median age at 
the onset of CLL is 72 years [11].
Alkylating drugs, such as chlorambucil and 
cyclophosphamide formed the basis of CLL therapy 
for many years. In the last two decades however, 
the number of therapeutic options used against 
this disease, has significantly increased. Currently, 
the armamentarium of medicinal products now 
approved includes amongst others; purine ana-
logues (fludarabine, cladribine, pentostatin) and 
monoclonal antibodies (rituximab, ofatumumab, 
alemtuzumab) [12]. The most difficult thera-
peutic decisions concern the so-called slow–go 
patients because the homogeneous, widely ac-
cepted standards for chemotherapy choice in that 
group of patients are absent. In particular, no 
homogeneous standard of management has been 
established for patients failing to qualify for treat-
ment with straining regimens: purine analogue in 
full doses + cyclophosphamide + rituximab. The 
current diagnostic and therapeutic recommenda-
tions made by the Polish Society of Hematology 
and Transfusion Medicine Workgroup on CLL 
suggest chlorambucil monotheraphy, rituximab in 
combination with chlorambucil, a purine analogue 
with cyclophosphamide in reduced dose with or 
without rituximab, rituximab in combination with 
bendamustine, monotherapy with fludarabine, 
cladribine, bendamustine or rituximab [13]. Chlo-
rambucil monotherapy, being until recently the 
“gold standard” of CLL treatment (in view of its 
relatively good tolerance and the possibility of 
long term oral administration and low cost), is still 
used as symptomatic treatment in elderly patients 
with comorbidities, or in subsequent lines of CLL 
therapy. COP (cyclophosphamide, vincristine, 
prednisone) and CHOP (cyclophosphamide, doxo-
rubicin, vincristine, prednisone) regimens are of 
similar significance. The choice of therapy depends 
on the experience of the physician and medical 
centre as well as current reimbursement policies.
Recently, the growing hopes of both clinical 
societies and government agencies responsible for 
drug registration have been raised by new groups 
of molecules: glycoengineered anti-CD20 antibo-
dies and B-cell receptor (BCR) signalling pathway 
kinase inhibitors, for which the preliminary results 
from clinical trials have proved very promising.
Obinutuzumab
Obinutuzumab is a humanised type II IgG1 sub-
class monoclonal antibody against the CD20 anti-
gen. Owing to glycoengineering of the Fc fragment, 
obinutuzumab has a higher affinity to FcgRIII 
receptors on effector cells, such as natural killer 
cells (NK), macrophages, monocytes, as compared 
with antibodies not modified with glycoengineer-
ing methods. In preclinical studies it was found 
that obinutuzumab induced direct cell death and 
mediated the process of antibody-dependent cel-
lular phagocytosis (ADCP), while inducing comple-
ment-dependent cytotoxity (CDC) to a significantly 
lesser degree than type I antibodies.
Obinutuzumab in combination with chlorambu-
cil was approved in the EU in 2014 (towards the end 
of 2013 by FDA) for treating adult patients with 
treatment-naïve chronic lymphocytic leukemia, in 
whom, in view of comorbidities, contraindications 
to full-dose fludarabine are present. The condition 
made for granting marketing authorisation to the 
manufacturer was to submit periodical drug safety 
reports, according to the requirements set out in 
the European Union Reference Date (EURD) list. 
The first periodical drug safety report is scheduled 
for submission eight months after registration of 
the drug in the EU [14].
The decision for approval was based mainly on 
the results of a phase 3 multi-centre, open-label, 
randomised, three-arm clinical trial, which as-
sessed the effectiveness and safety of obinutuzum-
ab administration in combination with chlorambucil 
vs therapy with rituximab combined with chloram-
bucil, or chlorambucil monotherapy in patients with 
treatment-naïve CLL and significant comorbidities 
and/or decreased creatinine clearance [15, 16].
All study subjects (n = 781) were randomised 
in a 2:2:1 ratio into one of the following arms:
• obinutuzumab and chlorambucil;
• rituximab and chlorambucil;
• chlorambucil monotherapy.
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Patients with CLL, in whom comorbidities 
were assessed, were enrolled; i.e. coexistent dise-
ase score exceeded 6 according to the Cumulative 
Illness Rating Scale or renal function impairment 
was present (creatinine clearance < 70 ml/min). 
Patients were excluded with impaired liver func-
tion (grade 3 in NCI-CTC scale), ASPAT and ALAT 
activities exceeding more than five times the upper 
limit of normal for longer than two weeks, bilirubin 
concentration exceeding more than three times the 
upper limit of normal and renal failure (creatinine 
clearance < 30 ml/min). Patients with at least one 
organ/system failure rated 4 points according to 
CIRS, with the exception of diseases of the eyes, 
ears, nose, throat and larynx, were also excluded 
from the trial. The median result of comorbidity 
assessment was 8. In 42% of the patients qualified 
for the trial, the creatinine clearance was below 
70 ml/min and the result of comorbidity assess-
ment according to CIRS was above 6 points. 34% 
of the patients were qualified only on the basis of 
assessing the comorbidities, and 23% solely on the 
basis of impaired renal function.
The majority of the subjects were given obinutu-
zumab intravenously at an initial dose of 1000 mg on 
the 1st, 8th and 15th days of the first treatment cycle. 
In each subsequent treatment cycle (cycles 2 to 6), 
subjects received 1000 mg obinutuzumab only on the 
1st day of the cycle. Chlorambucil was administered 
orally in 0.5 mg/kg body weight dose on the 1st and 
15th days of each treatment cycle (cycles 1 to 6). The 
baseline characteristics of the patients in individual 
groups were well balanced. The median age of the 
study subjects was 73 years, and 44% of the patients 
were aged 75 years, or more. At baseline, 225 of the 
patients were qualified as stage A, according to the Bi-
net classification, 42% as stage B and 36% as stage C.
The primary endpoint in that trial was the 
progression-free survival (PFS). The secondary 
endpoints included:
• overall survival (OS);
• progression-free survival assessed by an in-
dependent review committee (IRC);
• treatment response rates at the time of ther-
apy completion, including the proportion of 
patients testing negative for minimal residual 
disease (MRD);
• event-free survival (EFS);
• time to administration of a subsequent line of 
antileukemic treatment;
• adverse effects (AEs) rate.
During Phase 2 of the study, obinutuzumab 
treatment combined with chlorambucil was com-
pared with rituximab in combination with chloram-
bucil in 663 patients. The efficacy for both phases 
of the study are shown in the Table 1.
Table 1. Data on the effectiveness of treatment with obinutuzumab combined with chlorambucil, based on the registration 
study (NCT01010061) (source [16])
Tabela 1. Dane dotyczące skuteczności leczenia obinutuzumabem w połączeniu z chlorambucylem na podstawie badania 
rejestracyjnego (NCT01010061) (źródło [16])
Analyzed parameter Phase Ia Phase 2
Chlorambucil  
N = 118
Obinutuzumab  
+ chlorambucil  
N = 238
Rituximab 
+ chlorambucil  
N = 330
Obinutuzumab  
+ chlorambucil  
N = 333
Median PFS assessed by the  
investigator — months (percentage 
of patients with an event)
11.1 months 
(81.4%)
26.7 months 
(39.1%)
15.2 months 
(60.3%)
26.7 months 
(31.2%)
Relative risk and p-value  
(log rank stratified test)
0.18 (0.13; 0.24) 
p < 0.0001
0.39 (0.31; 0.49) 
p < 0.0001
Median PFS assessed by an indepen-
dent review committee (percentage 
of patients with an event)
11.2 months 
(76.3%)
27.2 months 
(37.4%)
14.9 months 
(55.5%)
26.7 months 
(30.9%)
Relative risk (RR) and p-value  
(log rank stratified test)
0.19 (0.14; 0.27) 
p < 0.0001
0.42 (0.33; 0.54) 
p < 0.0001
Index of responses to treatment  
after therapy completion (percenta-
ge of treatment-responders)
31.4% 77.3% 65.0% 78.4%
p-value (chi-square conformity test) p < 0.0001 p = 0.0001
Index of responses to treatment  
after therapy completion (percentage  
of complete remissions)
0.0% 22.3% 7.0% 20.7%
PFS — progression-free survival
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The median PFS assessed by the investiga-
tors was 26.7 months in the group treated with 
obinutuzumab combined with chlorambucil and 
11.1 months in the group treated with chlorambucil 
monotherapy (hazard ratio [HR] = 0.18, p < 0.001). 
A significant advantage in PFS was demonstrated 
for obinutuzumab combined with chlorambucil 
and also when compared with rituximab combined 
with chlorambucil (26.7 months vs. 15.2 months, 
respectively; HR = 0.39, p < 0.001).
The results of analysis of subgroups for PFS 
(according to gender, age, Binet clinical staging, 
CIRS score, beta2-microglobulin, IGHV mutational 
status, chromosomal abnormalities, lymphocyte 
count at baseline) were consistent with those 
observed in the general population of patients 
qualified for the treatment (intention-to-treat [ITT] 
analysis).
At the time of analysis median OS was not 
achieved in any of the study arms, however the 
results obtained suggest that administrating obi-
nutuzumab combined with chlorambucil showed 
a statistically significant survival improvement 
when compared with chlorambucil monotherapy. 
The mortality rate in individual groups was 9% 
vs. 20%, respectively (HR = 0.41; 95% confidence 
interval [CI], 0.23–0.74, p = 0.002). No statistically 
significant advantage was demonstrated in survival 
rates in the group treated with obinutuzumab com-
bined with chlorambucil over the group treated 
with rituximab in combination with chlorambucil 
(HR = 0.66; 95% CI: 0.41–1.06, p = 0.08). The 
mortality rates in these groups were 8% vs. 12%, 
respectively.
In summary, the risk of disease progression or 
patient death was lower in those groups receiving 
obinutuzumab combined with chlorambucil when 
compared with the group on rituximab with chlo-
rambucil and the group treated with chlorambucil 
monotherapy in all subgroups; with the exception 
of the subgroup of patients with the 17p deletion. 
In the small group of patients with this 17p dele-
tion, only a benefit was observed when compared 
with the group receiving chlorambucil (HR = 0.42, 
p = 0.0892); no benefit was seen when compared 
with the group on rituximab with chlorambucil. 
In individual subgroups, a reduction was found in 
the risk of disease progression or death, which 
was from 92% to 58% for the group treated with 
obinutuzumab and chlorambucil compared to the 
group receiving chlorambucil alone and from 
72% to 29% for the group on obinutuzumab with 
chlorambucil compared to the group treated with 
rituximab and chlorambucil.
It is worth stressing that in the assessment un-
dertaken during the treatment, using QLQC30 and 
QLQ-CLL-16 questionnaires, no significant differ-
ences were found for any subscale. The data from 
the follow-up period are limited, particularly for 
the group treated with chlorambucil monotherapy. 
Nevertheless, until now no data has been pub-
lished, which indicate any significant differences 
in the quality of life for the follow-up period. The 
assessment of health-associated quality of life de-
monstrated no statistically significant differences 
during the treatment period.
The registration study has shown that adverse 
events occurred most frequently in the group 
treated with obinutuzumab. Grade 3, or higher, ad-
verse reactions developed in 73% and 50%, when 
comparing the obinutuzumab-chlorambucil group 
with chlorambucil monotherapy; in 56% and 50%, 
comparing the rituximab-chlorambucil group with 
chlorambucil monotherapy; and, finally, in 70% and 
55% of patients when comparing the obinutuzumab– 
–chlorambucil and rituximab–chlorambucil groups.
The most frequent adverse events (irrespec-
tively of the degree of intensity) in patients from 
the group treated with obinutuzumab + chloram-
bucil compared with chlorambucil monotherapy in-
cluded infusion-related reactions, which developed 
in a majority of patients during the first treatment 
cycle (69% vs. 0%). However, the incidence of 
infusion-related reactions gradually decreased: 
from 65% with infusion of the first 1000 mg obi-
nutuzumab dose to below 3% with subsequent 
infusions. The symptoms of infusion-related reac-
tions usually included: dyspnoea, hypotension, 
nausea, vomiting, chills, fever and hot flushes. Less 
frequently neutropenia (40% vs. 18%) and throm-
bocytopenia (15% vs. 7%) were observed, and the 
rate of grade 3–5 infections was 16% in the obinu-
tuzumab group [14]. The most frequent grade 3, or 
higher, adverse events in patients from the group 
receiving obinutuzumab + chlorambucil, compared 
with chlorambucil monotherapy respectively, in-
cluded infusion-related reactions (12% vs. 0%), 
neutropenia (35% vs. 16%), thrombocytopenia 
(11% vs. 4%) and anemia (5% vs. 4%).
For the group receiving obinutuzumab 
+ chlorambucil in this study, compared with 
the group treated with rituximab + chloram-
bucil, the most frequently developing grade 3, 
or higher, adverse reactions respectively in-
cluded neutropenia (33% vs. 28%), infections 
(12% vs. 14%; including pneumonia in 4% 
vs. 5%, neutropenia with fever in 2% vs. 1%), 
infusion-related reactions (20% vs. 4%), thrombo-
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cytopenia (10% vs. 3%), leucopenia (4% vs. 1%) 
and tumour lysis syndrome (2% vs. 0%). In sum-
mary, grade 3, or higher, adverse reactions oc-
curred more frequently in the group treated with 
obinutuzumab + chlorambucil as compared with 
the group receiving rituximab + chlorambucil 
(70% vs. 55%). Deaths due to adverse reactions 
occurred more frequently in the group receiving 
obinutuzumab + chlorambucil than in the group on 
rituximab + chlorambucil (4% vs. 6%).
Ibrutinib
Ibrutinib is a strong, low molecular weight 
Bruton’s tyrosine kinase inhibitor. It was approved 
in the European Union (EU) in October 2014 (in 
February 2014 by the FDA) for treating adult CLL 
patients, who were given at least one previous ther-
apy, or treatment-naïve patients with 17p deletion 
or TP53 mutation, in whom chemoimmunotherapy 
administration is not appropriate. The safety of 
use and effectiveness of ibrutininb in patients with 
CLL was assessed in one uncontrolled and one 
randomised trial with a control group.
An open-label, uncontrolled, multicentre study 
(PCYC-1102-CA) involved 51 patients with recur-
rent and drug-refractory CLL, who were given 
a 420 mg dose once daily and 34 patients who 
received 840 mg once daily [17]. Ibrutinib was 
administered until disease progression or loss 
of patient tolerance to treatment. The primary 
endpoint was the safety of using two treatment 
regimens, based on the incidence and intensity of 
adverse events. The secondary endpoints included: 
OS, PFS, pharmacodynamics and pharmacokinetics 
of the drug. The response assessment was carried 
out at the end of the 2nd, 5th, 8th, 12th, 15th and 24th 
treatment cycles. The median age of the study sub-
jects was 68 years (range from 37 to 82 years), the 
median time after diagnosis — 80 months, and the 
median number of previous treatment lines — 4. At 
baseline, 39.2% of the patients were at clinical stage 
IV according to Rai, in 45.1% a bulky disease was 
found (tumour diameter ≥ 5 cm), in 35.3% the 17p 
deletion and in 31.4% the 11q deletion were both 
confirmed [18].
The overall response rate (ORR) was de-
termined by the investigators and IRC accord-
ing to IWCLL (International Workshop on CLL) 
2008 criteria. After the follow-up period (median 
16.4 months), the ORR in IRC assessment for 
51 patients with recurrent/refractory disease was 
64.7% (95% CI: 50.1%, 77.6%); all responses be-
ing partial (PR) [18]. Taking into account partial 
responses with lymphocytosis, the ORR was 
70.6% (two complete responses and 34 partial re-
sponses) in the group receiving the 420 mg dose. 
Ten patients (20%) in that group achieved PR with 
persistent lymphocytosis.
The treatment with ibrutinib led to long term 
responses irrespectively of the dose administered. 
The estimated 26-month PFS rate was 75% and the 
estimated OS rate was 83%. During the follow-up 
period, disease progression was found in 11 pa-
tients (13%) [18].
It is very significant that the ibrutinib-treated 
patients achieved a prolongation of the time to 
disease progression in spite of the genetic load 
of risk factors. In 28 patients with deletion of the 
short arm of chromosome 17 [del(17)(p13.1)] 
(a chromosome aberration linked with the poorest 
prognosis) — the estimated 26-month PFS rate 
was 57% and the estimated OS rate was 70%. The 
patients who discontinued ibrutinib treatment for 
reasons other than disease progression remained 
in the study and were followed up every three 
months until disease progression, starting another 
line of therapy, or death. After detecting disease 
progression or starting another line of antitumour 
treatment, the follow-up was limited only to sur-
vival status. A long term improvement of cytopenia 
during ibrutinib treatment was observed in 32 out 
of 41 (78%) patients with baseline thrombocytope-
nia, 27 out of 33 (82%) patients with anemia and 
24 out of 31 (77%) patients with neutropenia [17].
Another study was a Phase 3 open-label, 
randomized, multicentre study of superiority type 
(PCYC-1112-CA, RESONATE study), comparing 
ibrutinib with ofatumumab [19]. Patients with re-
current and drug-refractory CLL (n = 391) were 
randomised in a 1:1 ratio into groups receiving 
ibrutinib or ofatumumab. Ibrutinib was adminis-
tered in a 420 mg daily dose until disease progres-
sion or loss of tolerance, while ofatumumab was 
given in 12 doses (initial dose — 300 mg/week, 
then 2000 mg weekly). After disease progression, 
57 patients in the ofatumumab arm were qualified 
by crossover to receive ibrutinib. The median age 
of the study subjects was 67 years (range from 30 to 
88 years), 68% were males and 90% of the patients 
were Caucasians. All patients had a baseline fitness 
status of 0 or 1 according to ECOG. The median 
time to diagnosis was 91 months and the median 
number of previous therapies was 2. In 58% of the 
patients at least one leukemic tumor of diameter 
of 5 cm or more was found at baseline. In 32% of 
the patients  a 17p deletion were found and in 31% 
a 11q deletion.
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Ibrutinib significantly prolonged disease pro-
gression-free survival time, however the median 
had not been reached before the preliminary re-
sults were published (median follow-up time 
was 9.4 months). The median disease PFS in the 
ofatumumab group was 8.1 months whereas the 
relative risk of disease progression or death in the 
ibrutinib-treated group was HR = 0.22 (95% CI: 
0.15–0.32, p < 0.001). This means a reduced risk 
of disease progression or death in patients treated 
with ibrutinib by 78% compared with ofatumumab. 
After six months of treatment, 88% of patients in 
the ibrutinib group remained free of disease pro-
gression, compared with 65% in the ofatumumab 
group. The effect of ibrutinib on PFS was observed 
independently of the baseline characteristics of 
the patients.
In patients with deletion of the short arm of 
chromosome 17 deletion [del(17)(p13.1)], linked 
with the poorest prognosis, the median PFS was 
not attained by the ibrutinib group, compared 
with a median of 5.8 months in the ofatumumab 
group (relative risk for progression or death was: 
HR = 0.25; 95% CI: 0.14–0.45). After six months, 
83% of patients with this aberration in the ibruti-
nib group still lived without disease progression, 
compared with 49% in the ofatumumab group.
Ibrutinib, in comparison to ofatumumab, sig-
nificantly improved the patient OS (the relative risk 
of death in the ibrutinib group being: HR = 0.43; 
95% CI: 0.24–0.79, p = 0.005), meaning that the 
risk of death was reduced by 57%. After 12 months 
the OS rate was 90% in the ibrutinib group and 
91% in the ofatumumab group. Before publication 
of the preliminary results from the RESONATE 
study, 57 patients from the ofatumumab group were 
switched to ibrutinib by crossover after confirma-
tion of disease progression.
The survival results were based on analysing 
the data that were censored during the crossover 
switch of the patients between the groups. After 
12 months of the treatment the survival results 
were also analyzed in the non-censored analysis of 
susceptibility (relative risk of death: HR = 0.29, 
p = 0.001), in which OS rates were 90% in the 
ibrutinib group and 79% in the ofatumumab group. 
The advantage in effectiveness of ibrutininb over 
ofatumumab for OS was noted in all subgroups of 
the RESONATE study subjects.
The response rate, when measured indepen-
dently, was significantly higher in the ibrutinib group, 
compared with the ofatumumab group (Table 2). 
Partial responses were confirmed in 43% of pa-
tients on ibrutinib and 4% in the group on ofatu-
mumab (odds ratio [OR] = 17.4; 95% CI: 8.1–37.3, 
p < 0.01). In 20% of patients receiving ibrutinib 
a partial response with lymphocytosis was noted. 
Lymphocytosis was observed in 69% of patients 
treated with ibrutinib, in whom no disease pro-
gression was found. The response rates in the 
investigators’ opinion were significantly higher; 
being respectively 68% and 21% [19, 20].
The effectiveness was similar in all studied 
subgroups, including patients with and without the 
17p deletion; a predetermined stratification factor.
The treatment duration in the RESONATE 
study was longer in those patients receiving ibruti-
nib than in patients treated with ofatumumab (me-
dian treatment duration — 8.6 months [range from 
0.2 to 16.1] vs. 5.3 months [range from 0 to 7.4]). 
Table 2. Data on the effectiveness of treating patients with chronic lymphocytic leukemia with ibrutinib in the RESONATE 
study (source [19])
Tabela 2. Dane dotyczące skuteczności leczenia ibrutynibem chorych na przewlekłą białaczkę limfocytową w badaniu RESO-
NATE (źródło [19])
Endpoint Ibrutinib
N = 195
Ofatumumab
N = 196
Median PFS Not reached 8.1 months
HR = 0.215 (95% CI: 0.146–0.317)
Median OS* HR = 0.434 (95% CI: 0.238–0.789)
HR = 0.387 (95% CI: 0.216–0.695)
ORR acc. to IRC**
p < 0.0001
42.6% 4.1%
ORR including PR with lymphocytosis  
(ORR acc. to IRC)
p < 0.0001
62.6% 4.1%
*Overall survival (OS) medians had not been reached in both groups; **all, who developed partial response (PR); PFS — progression-free survival; HR — hazard ratio; 
ORR — overall response rate; IRC — independent review committee
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The most frequent non-hematological adverse 
events, developing in at least 20% of the patients, 
included: diarrhea, fatigue, fever and nausea in the 
group of ibrutinib, and fatigue, infusion-related re-
actions and coughing in the group on ofatumumab.
At least one adverse event of grade 3, or 
higher, was observed in 57% of the patients on 
ibrutinib and 47% of the patients from the ofa-
tumumab group. The grade 3, or higher, adverse 
events developed significantly higher in the ibru-
tinib group which respectively included mainly 
diarrhoea (4% vs. 2%) and atrial fibrillation (3% 
vs. 0%). The adverse events bleeding-related (ir-
respective of the degree of severity) significantly 
developed more frequently in the group of ibrutinib 
(44% vs. 12%). Furthermore, marked bleedings (of 
degree ≥ 3) were only reported in 1% of patients 
from the ibrutinib group and in 2% of patients 
on ofatumumab. The remaining adverse events, 
which developed more frequently in the ibrutinib 
group, irrespectively of their severity, included: 
rash (8% vs. 4%), fever (24% vs. 15%) and vision 
disturbances (10% vs. 3%). Infections were seen 
more frequently in the group on ibrutinib (70% 
vs. 54%), whilst the infection rate of grade 3, or 
higher, was similar in both groups (24% vs. 22%). In 
the ofatumumab group, infusion-related reactions, 
peripheral sensory neuropathy, urticaria, nocturnal 
hyperhidrosis and pruritus were more frequent. 
Basocellular and squamous cell carcinoma were 
observed in 4% of patients on ibrutinib and 2% of 
patients in the ofatumumab group, whilst other 
malignancies were respectively found in 3% and 
1% of the patients. Treatment discontinuation 
due to adverse events occurred in 4% of the study 
subjects in each group. The mortality rate due to 
the adverse events was 4% in the group of ibrutinib 
and 5% in the patients on ofatumumab. It should 
be stressed, however, that the incidence of adverse 
events did not take into account the longer expo-
sure of patients to the drug in the ibrutinib group. 
As mentioned by the investigators, the significantly 
longer (by over three months) duration of ibrutinib 
treatment could have significantly contributed to 
higher rates of some adverse events in that group 
of patients.
In the registration study, about 3/4 of the pa-
tients with CLL treated with ibrutinib demonstated 
a reversible increase in the lymphocyte count after 
therapy initiation (increase by ≥ 50% compared 
with the baseline value and exceeding the value of 
5000/μl), frequently observed with a reduction of 
lymphadenopathy. It was found that lymphocytosis 
was a pharmacodynamic effect and should not have 
been regarded as disease progression in the ab-
sence of other clinical data. Lymphocytosis usually 
occurred during the first several weeks of ibrutinib 
administration and usually regressed with time 
(median value 18.7 weeks in CLL patients) [18].
In September 2014, an one-arm Phase 2 study 
was published, conducted at the MD Anderson Can-
cer Center in Houston USA, which suggests that 
the combination of ibrutinib with rituximab may be 
an effective and well tolerated therapeutic option 
for CLL patients with unfavourable prognostic 
factors [21]. In all, 40 patients with symptomatic 
CLL were enrolled into the study 20 out of whom 
had the 17p deletion or the TP53 mutation (16 pa-
tients were previously treated and four were treat-
ment-naïve). In 13 cases, recurrent CLL with the 
11q deletion were observed. The remaining seven 
patients were previously subjected to first-line 
chemoimmunotherapy (median PFS < 36 months).
Subjects were given 420 mg ibrutinib once daily 
in 28-day cycles, in combination with rituximab 
administered once weekly in the first cycle and 
then once per cycle for another five cycles. The 
primary endpoint of the study was PFS in the 
ITT group.
In the 18th month of the study, the patient rates 
without disease progression were estimated at 
78% (95 CI: 60.58–88.45). In patients with the 17p 
deletion or TP53 mutation, the rate became 72% 
(95% CI: 45.56–87.55). Furthermore, in month 18, 
84% of the study subjects were still alive (95% CI: 
67.22–92.39). The patient rate in the subgroup with 
the 17p deletion or TP53 mutation was 78% (95% 
CI: 51.99–91.36). When comparing differences in 
health-related quality of life at the study begin-
ning and during treatment, patients treated with 
ibrutinib in combination with rituximab, reported 
a significant improvement in their general health 
and quality of life after six and 12 months, with 
simultaneous and significant body mass gain. The 
toxicity of this treatment regimen, in most cases, 
was limited to adverse events of grade 1–2. 25% of 
the patients developed diarrhoea, 35% developed 
bleeding events, in 37.5% nausea and in 17.5% 
suffered fatigue. Grade 3 infections occurred in 
10% of the patients.
This study reports promising observations 
concerning the effectiveness and safety of ibrutinib 
combined with rituximab in the treatment of CLL pa-
tients with a poor prognosis. They, however, require 
confirmation in randomised studies on a greater 
number of patients. The possibility seen here of ef-
fective drug use, even in patients with TP53 gene 
disorders, seems particularly significant.
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Idelalisib
Idelalisib — an oral, selective inhibitor of 
phosphatidylinositiol p110d 3-kinase (PI3kd) is the 
third drug granted breakthrough therapy status by 
the FDA and was approved in the USA in 2014 for 
treating CLL patients. This kinase is hyperactive 
in B-cellular malignancies and is of key importance 
for many signalling pathways that regulate the pro-
liferation, survival and accumulation of malignant 
cells in lymphoid tissues and bone marrow. Idela-
lisib induces apoptosis and inhibits proliferation 
in cell lines derived from malignant B cells and in 
primary tumour cells.
Idelalisib in 2014 was approved in the EU for use 
as a therapy combined with rituximab in the treat-
ment of those adult patients with CLL as follows:
• who had previously received at least one 
therapy, or
• as a first-line therapy in the case of 17p dele-
tion or TP53 mutation in patients, for whom 
no chemoimmunotherapy could be used.
The marketing authorisation holder has been 
obliged to submit periodical idelalisib safety reports 
and to submit, by the end of 2017, the final report 
on the Phase 3 GS-US-312-0116 study assessing 
the effectiveness and safety of idelalisib use in 
combination with rituximab in patients with prev-
iously treated CLL, together with the final data on 
the extension of the GS-US-312-0117 study.
The randomised, double blind and placebo- 
-controlled Phase 3 study (GS-US-312-0116) was 
the main one serving as the basis for drug ap-
proval [22]. The study randomised 220 subjects 
in a 1:1 ratio of the group receiving idelalisib 
in 150 mg dose twice daily in combination with 
rituximab, or to the group treated with placebo 
and rituximab. In most patients, unfavourable 
cytogenetic prognostic factors were present (in 
43.2% — the 17p deletion and/or the TP53 muta-
tion; in 83.6% — non-mutated IgVH genes). The 
median number of previous therapies was 3. All 
subjects were given rituximab intravenously in 
an initial dose of 375 mg/m2 body surface area and 
then 500 mg/m2 body surface area (eight infusions 
in total). The patients in idelalisib group, for whom 
disease progression was confirmed, could be given 
a higher drug dose (300 mg twice daily). The dis-
ease PFS was the primary endpoint of the study.
In week 24, the patient rate with no progres-
sion was 93% in the idelalisib group and 46% in 
the placebo (the corrected risk ratio for disease 
progression or death in the idelalisib group was: 
HR = 0.15 (95% CI: 0.08–0.28, p < 0.001). Dise-
ase progression occurred in 12 patients in the 
idelalisib group and 53 patients receiving placebo. 
The median PFS in the idelalisib group was not 
reached, whilst being 5.5 months in the placebo 
group (Table 3). The therapeutic effect of idelalisib 
was demonstrated in all predefined subgroups in-
Table 3. Results of idelalisib effectiveness in patients with treating chronic lymphocytic leukemia obtained in the 312-0116 
study, according to an independent review committee assessment (source [22])
Tabela 3. Wyniki skuteczności idelalisibu w leczeniu chorych na przewlekłą białaczkę limfocytową uzyskane w badaniu  
312-0116 według opinii niezależnej komisji (źródło [22])
Idelalisib + rituximab Placebo + rituximab
N = 110 N = 110
PFS Median (95% CI)
HR (95% CI)
P value
NR (10.7; NR) months 5.5 (3.8; 7.1) months
0.18 (0.1; 0.32)
< 0.0001
ORR Patient responding rates (95% CI)
Odds ratio (95% CI)
P value
74.5% 14.5%
17.28 (8.66; 34.46)
< 0.0001
LNR* Patient responding rates, (95% CI)
Odds ratio (95% CI)
P value
92.2% (85.1; 96.6) 5.9% (2.2; 12.5)
165.5 (52.17; 524.98)
< 0.0001
OS Median (95% CI)
HR (95% CI)
P value
NR (NR; NR) NR (12.8; NR)
0.28 (0.11; 0.69)
0.03
*LNR — lymph node response defined as obtained reduction by ≥ 50% of the sum of the products of the greatest perpendicular diameters of changes selected as indi-
ces; PFS — progression-free survival; CI — confidence interval; NR — not reached; HR — hazard ratio (relative risk); ORR — overall response rate; OS — overall survival
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cluding those stratified according to the presence 
of the 17p deletion or TP53 or IgVH mutations.
In month 12 it was found that OS in the ide-
lalisib group was significantly greater than that in 
the placebo group (92% vs. 80%). The corrected 
death risk ratio was; HR = 0.28 (95% CI: 0.09–0.86, 
p = 0.02). Before publishing the preliminary study 
results, the median OS was not reached in any 
group. Before the survival analysis was made, 
16 patients died; four in the idelalisib group and 
12 in the placebo group. The ORR was 81% (95% 
CI: 71–88) in the group of idelalisib and 13% 
(95% CI: 6–21) in the placebo group (OR = 29.92, 
p < 0.001). All responses were partial.
The assessment carried out by the IRC demon-
strated that the patient rate, in whom at least a 50% 
reduction of lymphadenopathy occurred, was sig-
nificantly higher in the idelalisib group, i.e. 93% 
(95% CI: 85–97) compared with 4% (95% CI: 1–10) 
in the placebo group (OR = 264, p < 0.001).
Compared with rituximab and placebo, the 
treatment with idelalisib combined with rituximab 
led to a statistically and clinically significant im-
provement in the physical state, social functioning 
and functional fitness assessed by the patients with 
a standardized FACT-LEU (Functional Assessment of 
Cancer Therapy — Leukemia) questionnaire, along 
with a significant improvement in anxiety, depression 
and common activities as measured according to the 
EQ-5D (EuroQoL Five-Dimensions) scale.
In over 90% of patients, at least one adverse 
event occurred. In the idelalisib group, the following 
were respectively reported more frequently than 
in the placebo group; neutropenia (55% vs. 49% 
abnormal laboratory test results), increased ami-
notransferase activity (35% vs. 19% abnormal 
laboratory test results), fever (29% vs. 16%), nau-
sea (24% vs. 21%), chills (22% vs. 16%), diarrhea 
(19% vs. 14%). In the idelalisib group the follow-
ing were respectively less frequently observed: 
anemia (25% vs. 30% abnormal laboratory test 
results), fatigue (24% vs. 27%), infusion-related 
reactions (15% vs. 28%), thrombocytopenia (17% 
vs. 26% abnormal laboratory test results), cough 
(15% vs. 25%) and dyspnea (11% vs. 19%). The 
adverse events in both groups were usually mild 
or moderately intense.
In 40% of the patients on idelalisib, at least 
one serious adverse event occurred, compared with 
35% in the placebo group. The most frequently 
reported serious adverse events in both groups 
respectively included; pneumonia (6% vs. 8%), 
fever (6% vs. 3%), neutropenic fever (5% vs. 6%) 
and sepsis (5% vs. 3%). Treatment discontinuation 
due to adverse events became necessary in 8% of 
the patients receiving idelalisib and 10% of the 
patients in the placebo group.
Discussion
The improvements in treatment outcomes for 
CLL patients, due to the marketing of the most 
modern molecularly-directed drugs, (in Poland, 
such drugs are not publicly reimbursed), has at-
tracted the attention of not just hematologists or 
oncologists, but the wider medical community; 
especially as such changes may also lead in the near 
future to similar approaches for treating of other 
diseases. A vital aspect of this progress benefits 
those patients with highly unfavourable prognostic 
factors like TP53 gene disorders and the elderly 
who suffer from many comorbidities. In the past, 
for safety reasons, these patients did not usually 
qualify for clinical trials despite constituting a size-
able proportion of those suffering with CLL.
Another promising aspect is an acquirement 
more detailed knowledge of the B cell antigen re-
ceptor’s role in the pathogenesis of CLL, thereby 
leading to the development of several low-mo-
lecular-weight inhibitors of important signalling 
pathways, which in turn, has opened a new era for 
targeted therapy in CLL.
Progress in CLL research, with confirmed 
scientific evidence, has suggested that significant 
improvements can be made in treating this condi-
tion, particularly regarding the clinically significant 
endpoints as when compared to current therapy 
standards. This has contributed to the FDA grant-
ing such drugs ‘breakthrough therapy status’ so as 
to hasten the drug registration process.
It should however be kept in mind that early 
stages of drug approval requires additional monitor-
ing of adverse events because of an insufficiently 
known safety profile [23]. In order to offer patients 
the highest level of protection in everyday clinical 
practice conditions, obinutuzumab, ibrutinib and 
idelalisib have been placed by the EMA on the 
European list of drugs that are included into the 
additional safety monitoring system [24].
Setting an official price for a medicinal product 
can be controversial with an adequate therapeutic 
benefit expressed in quality-adjusted life years 
(QALY). Polish legal regulations about the cost of 
obtaining a quality-adjusted life year require the 
manufacturer to estimate the so-called threshold 
price ie. threshold value of the drug price at which 
the ratio of the cost to the obtained health effects 
is not higher than the cost-effectiveness threshold 
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stipulated by the Agency for Health Technology 
Assessment and Tariff System. This may be contro-
versial in a situation when no final data on patient 
OS are available.
Obinutuzumab, ibrutinib and idelalisib sup-
plement the drug armamentarium hitherto used 
for treating CLL. Ibrutinib and idelalisib are a new 
alternative for patients with refractory/recurrent 
disease and also for treatment-naïve patients with 
the 17p deletion or TP53 mutation, in whom admin-
istration of chemoimmunotherapy is not indicated 
because of predicted poor effectiveness. These 
drugs enable a better control of disease progression 
and the quality of life to be achieved. The most seri-
ous adverse effects are also reduced as compared 
with traditional chemotherapy regimens. More-
over, obinutuzumab combined with chlorambucil 
offers additional therapeutic benefits to patients 
previously treated for CLL and may be a valuable 
first-line therapeutic option in elderly CLL patients 
with comorbidities.
An optimal sequential therapy with the 
afore-discussed drugs has not yet been established. 
Further studies on B cell receptors and inhibition 
of signalling pathways generated by these recep-
tors could be a promising source of new data. This 
would thereby significantly change the current 
paradigm for treating these CLL patients. Undoubt-
edly in the nearest future, clinicians treating CLL 
patients will face a significant challenge of treat-
ment individualisation, defining optimal therapy 
regimens and their sequence along with establish-
ing molecular biomarkers of predictive importance. 
However, the true availability of the new treatment 
regimens for patients will depend in the first place 
on future reimbursement regulations.
References
1. Expanded access to investigational drugs for treatment use. Fed. 
Regist. 2006; 71: 75148.
2. Shulman S.R., Brown J.S. The Food and Drug Administration’s 
early access and fast-track approval initiatives: how have they 
worked? Food Drug Law J. 1995; 50: 503–531.
3. Food and Drug Administration. FY 2012 Innovative drug ap-
provals. Silver Spring, FDA, December 2012. Avaible on: www.
fda.gov/downloads/aboutfda/reportsmanualsforms/reports/ 
/ucm330859.pdf. Data access: 30.09.2015.
4. Steenburg C. The Food and Drug Administration’s use of post-
-marketing (phase IV) study requirements: exception to the rule? 
Food Drug Law J. 2006; 61: 295–383.
5. Avaible on: http://www.fda.gov/forconsumers/byaudience/for-
-patientadvocates/speedingaccesstoimportantnewtherapies/ 
/ucm128291.htm. Data access: 30.09.2015.
6. Avaible on: http://www.fda.gov/forpatients/approvals/fast/ucm405397.
htm. Data access: 30.09.2015.
7. Avaible on: http://www.gpo.gov/fdsys/pkg/BILLS-112s3187enr/ 
/pdf/BILLS-112s3187enr.pdf. Data access: 30.09.2015.
8. Avaible on: http://www.fda.gov/downloads/Drugs/GuidanceCom-
plianceRegulatoryInformation/Guidances/UCM358301.pdf. Data 
access: 30.09.2015.
9. Avaible on: http://www.fda.gov/regulatoryinformation/legislation/ 
/federalfooddrugandcosmeticactfdcact/significantamendmentsto-
thefdcact/fdasia/ucm329491.htm. Data access: 30.09.2015.
10. Robak P., Smolewski P. Współczesne poglądy na leczenie przewlekłej 
białaczki limfocytowej. Acta Haematol. Pol. 2011; 42: 53–62.
11. National Cancer Institute, Surveillance Epidemiology and End 
Results. SEER Stat Facts Sheets: chronic lymphocytic leukemia. 
Avaible on: http://seer.cancer.gov/statfacts/html/clyl.html. Data 
access: 30.09.2015.
12. Robak T., Jamroziak K., Robak P. Current and emerging treatments 
for chronic lymphocytic leukemia. Drugs 2009; 69: 2415–2449.
13. Robak T., Hus I., Błoński J. et al. Rekomendacje diagnostyczne 
i terapeutyczne dla przewlekłej białaczki limfocytowej w 2014 r. 
— raport Grupy Roboczej PTHiT oraz PALG-CLL. Acta Haematol. 
Pol. 2014; 45: 221–239.
14. Charakterystyka Produktu Leczniczego — Gazyvaro.
15. Goede V., Fischer K., Busch R. et al. Chemoimmunotherapy with 
GA101 plus chlorambucil in patients with chronic lymphocytic 
leukemia and comorbidity: results of the CLL11 (BO21004) safety 
run-in. Leukemia 2013; 27: 1172–1174.
16. Goede V., Fischer K., Busch R. et al. Obinutuzumab plus chlo-
rambucil in patients with CLL and coexisting conditions. N. Engl. 
J. Med. 2014; 370: 1101–1110.
17. Byrd J.C., Furman R.R., Coutre S.E. et al. Targeting BTK with 
ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. 
J. Med. 2013; 369: 3 2–42.
18. Charakterystyka Produktu Leczniczego — Imbruvica.
19. Byrd J.C., Brown J.R., O’Brien S. et al.Ibrutinib versus ofatu-
mumab in previously treated chronic lymphoid leukemia. N. Engl. 
J. Med. 2014; 371: 213–223.
20. Hallek M., Cheson B., Catovsky D. et al. Response assessment in 
chronic lymphocytic leukemia treated with novel agents causing 
an increase of peripheral blood lymphocytes. Blood 2012 June 4. 
21. Burger J.A., Keating M.J., Wierda W.G. et al. Ibrutinib plus rituxi-
mab for patients with high-risk chronic lymphocytic leukaemia: 
a single-arm, phase 2 study. Lancet Oncol. 2014; 15: 1090–1099.
22. Furman R.R., Sharman J.P., Coutre S.E. et al. Idelalisib and rituxi-
mab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 
2014; 370: 997–1007.
23. Avaible on: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ 
/special_topics/document_listing/document_listing_000365.
jsp&mid=WC0b01ac058067bfff. Data access: 30.09.2015.
24. Avaible on: http://www.ema.europa.eu/docs/en_GB/document_li-
brary/Other/2013/04/WC500142453.pdf. Data access: 30.09.2015.
